23andMe halts product marketing

Share this article:

In the wake of a Warning Letter it received from the FDA on Nov. 22, genetic test maker 23andMe has put a halt to marketing its products, Reuters reports. The company has stopped its advertising on television, radio and online.

23andMe founder Anne Wojcicki noted in a blog post on Nov. 26 that the company had kept up a dialogue with the FDA since 2008 concerning its DNA test. However, in its letter, the FDA wrote that both of the company's applications for clearance (one in July of last year and one in September) had been withdrawn because it had not responded to requests for further information.

Wojcicki commented that the company had received feedback on the submissions and was behind in its responses. "We stand behind the data we return to customers," she said, "but we recognize that the FDA needs to be convinced of the quality of our data as well."

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.